Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team.
Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7.
Pediatric Myasthenia Gravis.
Peragallo JH.
Semin Pediatr Neurol. 2017 May;24(2):116-121. doi: 10.1016/j.spen.2017.04.003. Epub 2017 Apr 7.
Novel Immunotherapies for Myasthenia Gravis.
Nair SS, Jacob S.
Immunotargets Ther. 2023 Apr 4;12:25-45. doi: 10.2147/ITT.S377056. eCollection 2023.
Transient Neonatal Myasthenia Gravis as a Common Complication of a Rare Disease: A Systematic Review.
Lindroos JLV, Bjørk MH, Gilhus NE.
J Clin Med. 2024 Feb 17;13(4):1136. doi: 10.3390/jcm13041136.
Biological therapies for myasthenia gravis.
Uzawa A, Utsugisawa K.
Expert Opin Biol Ther. 2023 Mar;23(3):253-260. doi: 10.1080/14712598.2023.2184257. Epub 2023 Feb 28.
Diagnosis and treatment of myasthenia gravis.
Mantegazza R, Cavalcante P.
Curr Opin Rheumatol. 2019 Nov;31(6):623-633. doi: 10.1097/BOR.0000000000000647.
FcRn inhibitors: a novel option for the treatment of myasthenia gravis.
Zhu LN, Hou HM, Wang S, Zhang S, Wang GG, Guo ZY, Wu J.
Neural Regen Res. 2023 Aug;18(8):1637-1644. doi: 10.4103/1673-5374.363824.
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.
Menon D, Bril V.
Drugs. 2022 Jun;82(8):865-887. doi: 10.1007/s40265-022-01726-y. Epub 2022 May 31.
Myasthenia gravis-Pathophysiology, diagnosis, and treatment.
Tannemaat MR, Huijbers MG, Verschuuren JJGM.
Handb Clin Neurol. 2024;200:283-305. doi: 10.1016/B978-0-12-823912-4.00026-8.
Efgartigimod: First Approval.
Heo YA.
Drugs. 2022 Feb;82(3):341-348. doi: 10.1007/s40265-022-01678-3.
